Immunotherapy Drugs Market Size, Share & Trends Analysis Report, By Type (Monoclonal Antibodies,Checkpoint Inhibitors,Interferons & Interleukins,Other Immunotherapies), By Application (Hospitals,Clinics,Other End Users), Regional Outlook and Forecast to 2028

Report Summary

Eternity Insights can provide a deep dive research report highlighting the market and competitive in-telligence across the key segments of the market. The report also considers the impact of COVID-19 on the global Immunotherapy Drugs market. The report considers 2018-2020 historic period, 2021 as base year, and 2022-2028 as forecast period. The report includes quantitative analysis of the market supported by the mar-ket drivers, challenges, and trends to accurately map the market scenario and competition.

Immunotherapy Drugs market report is based on robust research methodology designed using blend of research ap-proaches developed using secondary/desk research and validated through the primary research and expert insights. Eternity Insights also uses paid data bases such as FACIVA, Hoovers, and other bench-marking and forecasting tools to provide accurate statistical analysis of supply and demand trends.

Key Research Highlights: Market Drivers

The Immunotherapy Drugs market is estimated to expand at a considerable growth rate during the forecast period ow-ing to increasing prevalence of venous diseases and increasing new product approvals to cater this demand. Rise in the awareness about the diseases, increasing importance of early diagnosis, and growing spending on chronic diseases are poised to boost the market growth. Moreover, the key players in the market are investing in research and development of technologically advanced products leading to increased utilization of the Immunotherapy Drugs products across developed and developing countries of the world.

Key Research Highlights: Market Restrains

Limited awareness about the diseases, high cost of products, low economical condition, and lack of favorable insurance systems restricts the adoption of Immunotherapy Drugs products across developing regions of the globe. However, launch of new products with low cost and increasing efforts for market penetration in these regions can offer lucrative growth opportunities for the players in the Immunotherapy Drugs market.

Key Research Highlights: Trends

Increasing research and development spending on Immunotherapy Drugs development has been the leading industry trend of Immunotherapy Drugs market

The leading players in the market are focused on developing products which are cost effective and high quality to tap the huge unaddressed opportunities in the developing regions. This can be wit-nessed from the increasing spending on research and development and growing number of new product approvals.

Global Immunotherapy Drugs Market Size, 2018-2028 (USD MILLION)

Market Segmentation

Key Market Players

• F. Hoffmann-La Roche Ltd. (UK)
• Pfizer Inc. (US)
• Merck & Co Inc. (US)
• Novartis International AG (UK)
• Johnson & Johnson (US)
• Sanofi (France)
• GlaxoSmithKline Plc (UK)
• Amgen Inc. (US)
• AbbVie Inc. (US)
• Boehringer Ingelheim (Germany)
• AstraZeneca (UK)
• Immatics Biotechnologies (Germany)
• BioNTech SE (Germany)
• Genmab A/S (Denmark)
• Gilead Sciences
• Inc. (US)
• NBE Therapeutics (UK)
• Teva Pharmaceuticals (Israel)
• Bayer AG (Germany)
• Bristol-Myers Squibb (US)
• Incyte Corporation (US)
• Juno Therapeutics (US)
• Bluebird Bio (US)
• Celldex Therapeutics
• Vitaeris (Canada)

Immunotherapy Drugs Market, By Type

• Monoclonal Antibodies
• Checkpoint Inhibitors
• Interferons & Interleukins
• Other Immunotherapies

Immunotherapy Drugs Market, By Application

• Hospitals
• Clinics
• Other End Users

Key Benefits To The Stake Holders

• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors
• Provision of market value (USD Billion) and volume (Tons) data for each segment and sub-segment
• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions and acquisitions in the past five years of companies profiled
• Extensive company profiles comprising of company overview, company insights, product benchmarking and SWOT analysis for the major market players
• The current as well as the future market outlook of the industry with respect to recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions

Table Of Contents

1 Methodology and Scope

1.1 Market segmentation & scope
1.2 Information Procurement

1.2.1 Purchased Database
1.2.2 Eternity’s Internal Database
1.2.3 Secondary sources & third-party perspectives
1.2.4 Primary Research

1.3 Information analysis
1.4 Market formulation & data visualization
1.5 Data validation & publishing

2 Executive Summary

3 Immunotherapy Drugs Market Variables, Trends & Scope

3.1 Market Dynamics

3.1.1 Market Driver Analysis
3.1.2 Market Restraints
3.1.3 Market Challenge Analysis
3.1.4 Market Opportunities
3.1.5 Micro & Macro Indicator

3.2 Impact of COVID-19 Pandemic on Global Immunotherapy Drugs Market

3.2.1 Overview of Changing Landscape
3.2.2 Pre-covid & Post-Covid Market Analysis

3.3 Market Attractiveness Analysis
3.4 Regulatory Scenario
3.5 Industry Trend Analysis- Historic and Future Trend Assessment
3.6 Merger & Acquisition
3.7 New System Launch/Approvals
3.8 Market Analysis Tools

3.8.1 Porter’s Five Forces
3.8.2 PEST Analysis
3.8.3 Value Chain Analysis

3.9 Key Company Ranking Analysis, 2020

4 Global Immunotherapy Drugs Market Analysis and Forecast, By Type

4.1 Overview & Definition
4.2 Key Trends
4.3 Global Immunotherapy Drugs Market Value (US$ Mn) Forecast, by Type (2019 – 2028)

4.2.1 Monoclonal Antibodies
4.2.2 Checkpoint Inhibitors
4.2.3 Interferons & Interleukins
4.2.4 Other Immunotherapies

4.4 Type Comparison Matrix
4.5 Global Immunotherapy Drugs Market Attractiveness, By Type

5 Global Immunotherapy Drugs Market Analysis and Forecast, By Application

5.1 Overview & Definition
5.2 Key Trends
5.3 Global Immunotherapy Drugs Market Value (US$ Mn) Forecast, by Application (2019 – 2028)

5.3.1 Hospitals
5.3.2 Clinics
5.3.3 Other End Users

5.4 Application Comparison Matrix
5.5 Global Immunotherapy Drugs Market Attractiveness, by Application

6 Global Immunotherapy Drugs Market Analysis and Forecast, By Region

6.1 Overview & Definition
6.2 Key Trends
6.3 Global Immunotherapy Drugs Market Value (US$ Mn) Forecast, by Region (2019 – 2028)
6.4 North America
6.5 Europe
6.6 Asia Pacific
6.7 Latin America
6.8 Middle East & Africa

7 Global Immunotherapy Drugs Market Attractiveness, by Region

8 North America Immunotherapy Drugs Market Analysis and Forecast

8.1 Key Findings
8.2 North America Immunotherapy Drugs Market Analysis (US$ Mn) and Forecast, By Type (2019-2028)

8.2.1 Monoclonal Antibodies
8.2.2 Checkpoint Inhibitors
8.2.3 Interferons & Interleukins
8.2.4 Other Immunotherapies

8.3 North America Immunotherapy Drugs Market Analysis (US$ Mn) and Forecast, By Application (2019-2028)

8.3.1 Hospitals
8.3.2 Clinics
8.3.3 Other End Users

8.4 North America Immunotherapy Drugs Market Analysis (US$ Mn) and Forecast, By Country (2019-2028)

8.4.1 U.S.
8.4.2 Canada
8.4.3 Rest of North America

8.5 North America Immunotherapy Drugs Market Attractiveness Analysis

8.5.1 By Type
8.5.2 By Application
8.5.3 By Country

9 Europe Immunotherapy Drugs Market Analysis and Forecast

9.1 Key Findings
9.2 Europe Immunotherapy Drugs Market Analysis (US$ Mn) and Forecast, By Type (2019-2028)

9.2.1 Monoclonal Antibodies
9.2.2 Checkpoint Inhibitors
9.2.3 Interferons & Interleukins
9.2.4 Other Immunotherapies

9.3 Europe Immunotherapy Drugs Market Analysis (US$ Mn) and Forecast, By Application (2019-2028)

9.3.1 Hospitals
9.3.2 Clinics
9.3.3 Other End Users

9.4 Europe Immunotherapy Drugs Market Analysis (US$ Mn) and Forecast, By Country (2019-2028)

9.4.1 U.K.
9.4.2 Germany
9.4.3 France
9.4.4 Italy
9.4.5 Rest of Europe

9.5 Europe Immunotherapy Drugs Market Attractiveness Analysis

9.5.1 By Type
9.5.2 By Application
9.5.3 By Country

10 Asia Pacific Immunotherapy Drugs Market Analysis and Forecast

10.1 Key Findings
10.2 Asia Pacific Immunotherapy Drugs Market Analysis (US$ Mn) and Forecast, By Type (2019-2028)

10.2.1 Monoclonal Antibodies
10.2.2 Checkpoint Inhibitors
10.2.3 Interferons & Interleukins
10.2.4 Other Immunotherapies

10.3 Asia Pacific Immunotherapy Drugs Market Analysis (US$ Mn) and Forecast, By Application (2019-2028)

10.3.1 Hospitals
10.3.2 Clinics
10.3.3 Other End Users

10.4 Asia Pacific Immunotherapy Drugs Market Analysis (US$ Mn) and Forecast, By Country (2019-2028)

10.4.1 China
10.4.2 India
10.4.3 Japan
10.4.4 South Korea
10.4.5 Rest of APAC

10.5 Asia Pacific Immunotherapy Drugs Market Attractiveness Analysis

10.5.1 By Type
10.5.2 By Application
10.5.3 By Country

11 Latin America Immunotherapy Drugs Market Analysis and Forecast

11.1 Key Findings
11.2 Latin America Immunotherapy Drugs Market Analysis (US$ Mn) and Forecast, By Type (2019-2028)

11.2.1 Monoclonal Antibodies
11.2.2 Checkpoint Inhibitors
11.2.3 Interferons & Interleukins
11.2.4 Other Immunotherapies

11.3 Latin America Immunotherapy Drugs Market Analysis (US$ Mn) and Forecast, By Application (2019-2028)

11.3.1 Hospitals
11.3.2 Clinics
11.3.3 Other End Users

11.4 Latin America Immunotherapy Drugs Market Analysis (US$ Mn) and Forecast, By Country (2019-2028)

11.4.1 Brazil
11.4.2 Rest of Latin America China

11.5 Latin America Immunotherapy Drugs Market Attractiveness Analysis

11.5.1 By Type
11.5.2 By Application
11.5.3 By Country

12 Middle East & Africa (MEA) Immunotherapy Drugs Market Analysis and Forecast

12.1 Key Findings
12.2 Middle East & Africa (MEA) Immunotherapy Drugs Market Analysis (US$ Mn) and Forecast, By Product Type (2019-2028)

12.2.1 Monoclonal Antibodies
12.2.2 Checkpoint Inhibitors
12.2.3 Interferons & Interleukins
12.2.4 Other Immunotherapies

12.3 Middle East & Africa (MEA) Immunotherapy Drugs Market Analysis (US$ Mn) and Forecast, By Application (2019-2028)

12.3.1 Hospitals
12.3.2 Clinics
12.3.3 Other End Users

12.4 Middle East & Africa (MEA) Immunotherapy Drugs Market Analysis (US$ Mn) and Forecast, By Country (2019-2028)

12.4.1 GCC Countries
12.4.2 South Africa
12.4.3 Rest of MEA

12.5 Middle East & Africa (MEA) Immunotherapy Drugs Market Attractiveness Analysis

12.5.1 By Type
12.5.2 By Application
12.5.3 By Country

13 Competitive Landscape

13.1 Market Players – Competition Matrix
13.2 Market Share Analysis by Key Players, 2020 (%)
13.3 Company Profiles

13.3.1 F. Hoffmann-La Roche Ltd. (UK)

13.3.1.1 Company Overview
13.3.1.2 Company Snapshot
13.3.1.3 Financial Overview
13.3.1.4 Product Portfolio
13.3.1.5 Key Developments/Strategies

13.3.2 Pfizer Inc. (US)
13.3.3 Merck & Co Inc. (US)
13.3.4 Novartis International AG (UK)
13.3.5 Johnson & Johnson (US)
13.3.6 Sanofi (France)
13.3.7 GlaxoSmithKline Plc (UK)
13.3.8 Amgen Inc. (US)
13.3.9 AbbVie Inc. (US)
13.3.10 Boehringer Ingelheim (Germany)
13.3.11 AstraZeneca (UK)
13.3.12 Immatics Biotechnologies (Germany)
13.3.13 BioNTech SE (Germany)
13.3.14 Genmab A/S (Denmark)
13.3.15 Gilead Sciences
13.3.16 Inc. (US)
13.3.17 NBE Therapeutics (UK)
13.3.18 Teva Pharmaceuticals (Israel)
13.3.19 Bayer AG (Germany)
13.3.20 Bristol-Myers Squibb (US)
13.3.21 Incyte Corporation (US)
13.3.22 Juno Therapeutics (US)
13.3.23 Bluebird Bio (US)
13.3.24 Celldex Therapeutics
13.3.25 Vitaeris (Canada)

14 Key Takeaways